======= PCGF5 ======= == Gene Information == * **Official Symbol**: PCGF5 * **Official Name**: polycomb group ring finger 5 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=84333|84333]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q86SE9|Q86SE9]] * **Interactions**: [[https://thebiogrid.org/search.php?search=PCGF5&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PCGF5|Open PubMed]] * **OMIM**: [[https://omim.org/entry/617407|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Component of a Polycomb group (PcG) multiprotein PRC1- like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332). Plays a redundant role with PCGF3 as part of a PRC1-like complex that mediates monoubiquitination of histone H2A 'Lys-119' on the X chromosome and is required for normal silencing of one copy of the X chromosome in XX females (By similarity). {ECO:0000250|UniProtKB:Q3UK78, ECO:0000269|PubMed:26151332}. |zf-C3HC4| |inactivation of X chromosome by genetic imprinting| |X chromosome| |histone H2A-K119 monoubiquitination| |PRC1 complex| |dosage compensation by inactivation of X chromosome| |histone H2A monoubiquitination| |regulation of gene expression by genetic imprinting| |dosage compensation| |genetic imprinting| |histone H2A ubiquitination| |PcG protein complex| |histone monoubiquitination| |histone ubiquitination| |protein monoubiquitination| |regulation of gene expression, epigenetic| |RNA polymerase II regulatory region sequence-specific DNA binding| |histone modification| |covalent chromatin modification| |centrosome| |DNA-binding transcription factor activity| |protein ubiquitination| |chromatin organization| |protein modification by small protein conjugation| |nucleolus| |protein modification by small protein conjugation or removal| |chromosome organization| |positive regulation of transcription by RNA polymerase II| |positive regulation of transcription, DNA-templated| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |positive regulation of RNA metabolic process| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp141|Nifurtimox 1μM R03 exp141]]|-2.05| |[[:results:exp278|CVT-10216 0.1μM R06 exp278]]|-1.88| |[[:results:exp376|Losmapimod 1μM R07 exp376]]|-1.77| |[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-1.74| |[[:results:exp537|WNT3A 44ng/ml R08 exp537]]|1.85| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 1/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|1/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 16901 * **Expression level (log2 read counts)**: 5.67 {{:chemogenomics:nalm6 dist.png?nolink |}}